Bell LE, Bardelle C, Packer MJ, Kastl J, Holdgate GA, Davies G. (2024). Characterisation of high throughput screening outputs for small molecule degrader discovery. SLAS Discovery, vol 29, doi:10.1016/j.slasd.2024.100162
Holdgate GA, Bardelle C, Berry SK, Lanne A, Cuomo ME. (2023). Screening for molecular glues-Challenges and opportunities. SLAS Discovery, vol 29, doi: 10.1016/j.slasd.2023.12.008.
Winter-Holt, J. J., Bardelle, C., Chiarparin, E., Dale, I. L., Davey, P. R. J., Davies, N. L., … Guichard, S.(2022). Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models. Journal of Medicinal Chemistry, Vol. 65. doi:10.1021/acs.jmedchem.1c01871
Holdgate, G. A., Bardelle, C., Lanne, A., Read, J., O'Donovan, D. H., Smith, J. M., … Sheppard, R. (2022). Drug discovery for epigenetics targets. Drug Discovery Today, Vol. 27.doi:10.1016/j.drudis.2021.10.020
Clare, R. H., Bardelle, C., Harper, P., Hong, W. D., Börjesson, U., Johnston, K. L., … Ward, S. A. (2019).Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. Nature Communications, 10. doi:10.1038/s41467-018-07826-2
Bardelle, C., Sauzeau, V., Carter, M. B., Liu, Z., Loirand, G., & Murray, D. (2018). High Throughput Screen for Inhibitors of Rac1 GTPase by Flow Cytometry. doi:10.5772/intechopen.71074
Ding, M., Clark, R., Bardelle, C., Backmark, A., Norris, T., Williams, W., … Howes, R. (2018). Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective. SLAS Discovery, 23. doi:10.1177/2472555218775074
Bardelle, C., & Boros, J. (2017). ATM kinase inhibitors: HTS cellular imaging assay using cellomicsTM arrayscan VTI platform. Methods Mol Biol, doi:10.1007/978-1-4939-6955-5_5
Ding, M., Kaspersson, K., Murray, D., & Bardelle, C. (2017). High-throughput flow cytometry for drug discovery: principles, applications, and case studies. Drug Discovery Today, Vol. 22. doi:10.1016/j.drudis.2017.09.005
Durant, S. T., Karlin, J., Pike, K., Colclough, N., Mukhopadhyay, N., Ahmad, S. F., … Valerie, K. (2016). Abstract 3041: Blood-brain barrier penetrating ATM inhibitor (AZ32) radiosensitises intracranial gliomas in mice. Cancer Research, 76. doi:10.1158/1538-7445.am2016-3041
Bardelle, C., McWilliams, L., Mounfield, S., Wigglesworth, M., & Rich, K. (2015). Validation of Miniaturized One-Step Reverse Transcription qPCR Assays for High-Throughput Screening and Comparison to a Reporter Gene Methodology. Assay and Drug Development Technologies, 13. doi:10.1089/adt.2014.630
Kettle, J. G., Ballard, P., Bardelle, C., Cockerill, M., Colclough, N., Critchlow, S. E., … Whittaker, D. (2015). Discovery and optimization of a novel series of dyrk1b kinase inhibitors to explore a MEK resistance hypothesis. Journal of Medicinal Chemistry, 58. doi:10.1021/acs.jmedchem.5b00098
Bardelle, C., & Boros, J. (2012). Development of a high-content high-throughput screening assay for the discovery of ATM signaling inhibitors. Journal of Biomolecular Screening, 17. doi:10.1177/1087057112448529
Bardelle, C., Barlaam, B., Brooks, N., Coleman, T., Cross, D., Ducray, R., … Read, J. (2011). ChemInform Abstract: Inhibitors of the Tyrosine Kinase EphB4. Part 3. Identification of Non‐benzodioxole‐Based Kinase Inhibitors. ChemInform, 42. doi:10.1002/chin.201107189
Allen, J. V., Bardelle, C., Blades, K., Buttar, D., Chapman, L., Colclough, N., … Slater, A. M. (2011). The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach. Bioorganic and Medicinal Chemistry Letters, 21. doi:10.1016/j.bmcl.2011.07.047
Barlaam, B., Ducray, R., Brempt, C. L. V. D., Plé, P., Bardelle, C., Brooks, N., … Read, J. (2011). Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. Bioorganic and Medicinal Chemistry Letters, 21. doi:10.1016/j.bmcl.2011.03.009
Bardelle, C., Barlaam, B., Brooks, N., Coleman, T., Cross, D., Ducray, R., … Read, J. (2010). Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 20. doi:10.1016/j.bmcl.2010.08.100
Bardelle, C., Coleman, T., Cross, D., Davenport, S., Kettle, J. G., Ko, E. J., … Williams, E. J. (2008). Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. Bioorganic and Medicinal Chemistry Letters, 18. doi:10.1016/j.bmcl.2008.09.087
Whitfield, J., Harada, K., Bardelle, C., & Staddon, J. M. (2003). High-throughput methods to detect dimerization of Bcl-2 family proteins. Analytical Biochemistry, 322. doi:10.1016/j.ab.2003.07.014
Bardelle, C., Smales, C., Ito, M., Nomoto, K., Wong, E. Y. M., Kato, H., … Staddon, J. M. (1999). Phosphodiesterase 4 conformers: Preparation of recombinant enzymes and assay for inhibitors. Analytical Biochemistry, 275. doi:10.1006/abio.1999.4321
Bardelle C, Furie B, Furie BC, Gilbert GE. (1993). Membrane binding kinetics of factor VIII indicate a complex binding process. Journal of Biological Chemistry, 268. PMID: 8473326
Bihoreau N, Paolantonacci P, Bardelle C, Fontaine-Aupart MP, ... J, Romet-Lemonne JL. (1991).Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain. Biochemical Journal, 277. doi: 10.1042/bj2770023
